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The regulation of gastric acid secretion is a complex system, which has been
elucidated over a number ofyears. The significance ofthe primary role ofhistamine
as astimulant oftheparietal cellwasprovenconclusivelybythedemonstration ofthe
efficacy ofH2-receptor blockers [1]. The involvement ofthevagal and neural system,
primarily via muscarinic receptors, appears important, but its exact role in the
secretion of acid remains to be determined fully. For some time, the role played by
antral gastrin has been of primary interest to investigators of parietal cell function.
While this role was for some considerable time proposed to be via direct action on
the parietal cell, it has become obvious recently that this effect may be mediated
predominantlyvia the ECL-cell system ofthe fundic mucosa.
The biology of the enterochromaffin-like (ECL) cell has been described in
considerable detail in this section. Recognition ofits function and delineation ofits
secretory components have become a source of considerable interest to both
physiologists andclinicians. Aparticular reason forthis interest hasbeen recognition
ofthe fact that one ofthe consequences oflong-term sustained acid inhibition is the
generation of ECL hyperplasia [2]. In rodent species studied, this condition may
develop from hyperplasia via a series of stages into neoplasia (carcinoid). Thus the
question ofECL-cell hyperplasia has become an important biological issue and may
be of some considerable clinical significance. The study of the interrelationship
between the parietal cell and the ECL cell has thus become a focal issue in the area
ofgastric clinical and scientific endeavor.
Although the ECL cell was first noted some 20 years ago, like many of the
endocrine cells of the gut, no specific function was clearly definable. The identifica-
tion of major amounts of histamine in the cell led to examination of the possibility
that it might be the source ofthe histamine responsible for parietal cell stimulation
[3]. Prior to this theory, it had been long held that the primary source ofhistamine in
the gastric mucosa was chiefly from mast cells. Further examination of the question
revealed that the ECL cell contained abundant histamine and histidine decarboxyl-
ase, and that stimulation by gastrin released amounts of histamine at levels capable
of stimulating parietal cell secretion [4]. The resultant focus on the ECL cell as a
primary regulator of gastric acid secretion and possibly even mucosal trophic
regulation has resulted in a series of elegant studies in this area by a number of
groups.
To date, progress with the evaluation ofthis cell's function has, to a major extent,
been limited by the unavailability ofpure cell preparation. More recently, however,
Prinz and his colleagues have generated a relatively pure ECL-cell preparation from
rodents and been able to delineate certain aspects of the secretory functions ofthis
cell [5]. Thus the ECL cell has been demonstrated to secrete histamine at physiolog-
ical levels ofgastrin stimulation and to respond to carbachol, forskolin, and epineph-
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rine stimulation. Furthermore, thegastrinstimulationofhistaminerelease isinhibited
by somatostatin, confirming previous reports of receptors for both gastrin and
somatostatin on the ECLcell [6].
Ofparticular interest, however, hasbeen the demonstration ofECL-cell hyperpla-
sia under conditions of acid inhibition. This condition occurs in disease states
(atrophic gastritis, pernicious anemia) or is induced by pharmacotherapeutic agents
[7]. While the exact clinical relationship of ECL-cell hyperplasia and its putative
sequence to neoplasia remains to be defined, it appears at this stage to be a relatively
insignificant clinical entity in terms of incidence. The long-term consequences have,
however, not yet been fully evaluated in patients. The biological significance of the
mechanism responsible for the phenomenon may be of considerable interest and
pertinence. Under conditions of atrophic gastritis or pernicious anemia, ECL-cell
hyperplasia iswell documented, and its ability to progress to a gastric carcinoid type
of pathology accepted. Similarly, in patients with gastrinoma suffering from the
multiple endocrine neoplasia type 1 (MEN-1) syndrome, the documented ECL-cell
hyperplasia of the non-familial Zollinger-Ellison (ZE) syndromes appears to evolve
into gastric carcinoid tumors when these patients are exposed to potent and
sustained acid inhibitory therapy [8]. Under general circumstances, however, the
modest ECL-cell hyperplasia noted to occurwith potent acid inhibitory agents seems
to regress on cessation of acid inhibitory therapy. The relationship between acid
inhibition and ECL-cell hyperplasia has been attributed to the associated hypergas-
trinemia. The hypothesis proposed has suggested that hypergastrinemia generates a
trophic signal to the ECLcells, resulting inthe hyperplasia and subsequent neoplasia
[9]. Recent observations regarding the production of transforming growth factor a-
(TGFcx) by parietal cells and studies implicating histamine itself in the proliferation
of ECLcells suggest that the issue may be of a more complex nature. An interesting
animal model, Mastomys, a sub-Saharan rodent, has been studied in that respect.
Although this animal develops spontaneous ECLomas at approximately 18 months
of age, these are unassociated with hypergastrinemia, but do secrete large amounts
ofhistamine. Conversely, however, when these animals are placed on acid inhibitory
therapy for three to four months, they rapidly develop hypergastrinemia, ECL-cell
hyperplasia, andneoplasia [10]. Paradoxically, theutilizationofHI-receptorblockers
substantially inhibits the development of ECL-cell hyperplasia and neoplasia. In
addition, somatostatin analogs similarly inhibit significantly the development of
ECL-cell hyperplasia and neoplasia under these circumstances [11].
A further question of clinical concern that has been raised in this regard is the
possibility that the generation ofECL-cell hyperplasia mayin somewaybe related to
the subsequent development ofgastric adenocarcinoma. The basis for this proposal
underlies the observations that most gastric carcinomas evolve in a low-acid environ-
ment and that some gastric tumors, when carefully studied, demonstrate a mixed
endocrine andadenocarcinomatoushistologicalpicture. Thisobservationhasaroused
considerable interest, but its exact clinical and scientific significance remains to be
proven.
Study ofthe ECL cell has become a subject ofprominence and importance at this
time. The two critical areas that need to be delineated and appropriately defined are
the regulation ofhistamine secretion and the trophic regulatory effect ofgastrin. It is
possible that the ECL cell may possess more than one type of gastrin receptor
responsible for either stimulation of histamine secretion or alteration of ECL-cell
replication rates. Delineation of the mechanisms of histamine secretion by the cell
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are ofimportance and may be applicable to the further evaluation of acid inhibitory
therapy. The elucidation of the histogenesis and biology of ECL-cell hyperplasia is
important from two points of view: first, in the understanding of the biochemical
effectsofthe pharmacotherapeutic probes ofacid inhibition on ECL-cell replication,
and, second, in enabling appreciation ofthe cellular regulatorymechanisms involved
in growth regulation of the gastric mucosa. The fact that the parietal cell of the
stomach is known to secrete TGFa may be of importance in evaluating the further
interactions of the ECL and the parietal cell. Since some ECL cells have been
reported to contain PYY and enteroglucagon-like substances, this type of cell, too,
may have an as yet undefined trophic function.
At this time, the ECL cell has been difficult to study since it represents less than 2
percent of the mucosal fraction of the gastric fundic mucosa. Furthermore, it has,
until recently, been an Augean task to isolate and study, not only in pure form, but
also in sufficient numbers to allowforcritical evaluation ofitsfunctional processes. A
further difficulty has been the inability to culture ECL cells and to define their
trophic regulation. In this regard, the possible relationship of histamine as a
mitogenic agent in ECL-cell replication needs to be evaluated further. Similarly, the
delineation of the biochemical basis of a direct parietal cell feedback loop on
ECL-cell proliferation and function needs tobe explored.
While the ECLcell is a relative newcomer to thefield ofgastric functional cells, its
debut has generated scientific and clinical interest. Its role in acid secretion appears
to be pivotal, while its place in the regulation ofmucosal growth is worthy offurther
examination. Indeed, the elucidation of the trophic regulatory mechanisms of the
ECL cell may provide information helpful in the elucidation ofthe genesis ofgastric
neoplasia. Thus, although the ECL cell has been difficult to identify and hard to
evaluate, its probable significance suggests that it isworthy ofserious study.
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